JOINN Laboratories (China) Co., Ltd. Class H (HK:6127) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
JOINN Laboratories has entered into a 2025 service agreement with Staidson, promising to deliver a comprehensive suite of pharmaceutical research and development services. This partnership, effective from January 2025, highlights a strategic collaboration in non-clinical and clinical trial stages. The agreement is categorized as a continuing connected transaction under the Hong Kong Stock Exchange rules.
For further insights into HK:6127 stock, check out TipRanks’ Stock Analysis page.